Timeline
2019
2020
- Langen Junior Science Award
- WHO Declares Pandemic
- Paul Ehrlich and Ludwig Darmstaedter Prize
- Supply Bottleneck for Pneumococcal Vaccines
- Blood Donation Remains Possible
- Convalescent Plasma: First Clinical Trial
- COVID-19 Vaccines: First Clinical Trial
- Marketing Authorisation of Gene Therapy
- COVID-19 Vaccines: Second Clinical Trial Approved
- German Presidency of the EU Council
- COVID-19 Vaccines: Two Clinical Trials Approved
- Another Clinical Trial Approved
- Start of Two Rolling Review Procedures
- Allergen Products: European Standards
- Allergen Product: First European Marketing Authorisation
- COVID-19 Peptide Vaccine: First Clinical Trial
- COVID-19 Vaccine: Third Rolling Review Procedure
- Validation of COVID-19 Rapid Tests
- First Marketing Authorisation of a COVID-19 Vaccine
- SafeVac App Available
On 21 December 2020, the European Commission issues a conditional marketing authorisation for the BioNTech/Pfizer mRNA vaccine against COVID-19. This follows a recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on the same day.
On the next day, the Paul-Ehrlich-Institut releases the first vaccine batches for the German and European market. At an early stage, experts from the Paul-Ehrlich-Institut had developed and validated test methods for testing the innovative mRNA vaccines.